A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

Matthew B Laurens, Sodiomon B Sirima, Elizabeth T Rotrosen, Mohamadou Siribie, Alfred Tiono, Alphonse Ouedraogo, Yuanyuan Liang, Leslie P Jamka, Karen L Kotloff, Kathleen M Neuzil, Matthew B Laurens, Sodiomon B Sirima, Elizabeth T Rotrosen, Mohamadou Siribie, Alfred Tiono, Alphonse Ouedraogo, Yuanyuan Liang, Leslie P Jamka, Karen L Kotloff, Kathleen M Neuzil

Abstract

The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533.

Keywords: Burkina Faso; child; conjugate; immunogenicity; typhoid-paratyphoid vaccines.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Trial flow diagram. EPI, Expanded Program on Immunization; IPV, inactivated poliovirus vaccine; MCV-A, meningococcal A conjugate vaccine; MR, measles-rubella vaccine; Vi-TCV, Vi-typhoid conjugate vaccine; YFV, yellow fever vaccine.

References

    1. Marks F, von Kalckreuth V, Aaby P, et al. . Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 2017; 5:e310–23.
    1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346–53.
    1. Dekker D, Krumkamp R, Eibach D, et al. . Characterization of Salmonella enterica from invasive bloodstream infections and water sources in rural Ghana. BMC Infect Dis 2018; 18:47 Available at: .
    1. Al-Emran HM, Eibach D, Krumkamp R, et al. . A multicountry molecular analysis of Salmonella enterica serovar typhi with reduced susceptibility to ciprofloxacin in sub-Saharan Africa. Clin Infect Dis 2016; 62(Suppl 1):S42–6.
    1. Al-Emran HM, Hahn A, Baum J, et al. . Diagnosing Salmonella enterica serovar typhi infections by polymerase chain reaction using EDTA blood samples of febrile patients from Burkina Faso. Clin Infect Dis 2016; 62(Suppl 1):S37–41.
    1. Al-Emran HM, Krumkamp R, Dekker DM, et al. . Validation and identification of invasive Salmonella serotypes in Sub-Saharan Africa by multiplex polymerase chain reaction. Clin Infect Dis 2016; 62(Suppl 1):S80–2.
    1. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49–59.
    1. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM.. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis 2015; 61:393–402.
    1. Meiring JE. TyVAC Malawi: a phase III randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children age 9 months through 12 years in Blantyre, Malawi: study protocol for a randomized clinical trial. Clin Infect Dis 2018.
    1. Tarzaali A, Viens P, Quevillon M. Inhibition of the immune response to whooping cough and tetanus vaccines by malaria infection, and the effect of pertussis adjuvant. Am J Trop Med Hyg 1977; 26:520–4.
    1. Greenwood BM, Bradley AK, Blakebrough IS, Whittle HC, Marshall TF, Gilles HM. The immune response to a meningococcal polysaccharide vaccine in an African village. Trans R Soc Trop Med Hyg 1980; 74:340–6.
    1. Simondon F, Preziosi MP, Pinchinat S, et al. . Randomised study of the possible adjuvant effect of BCG vaccine on the immunogenicity of diphtheria-tetanus-acellular pertussis vaccine in Senegalese infants. Eur J Clin Microbiol Infect Dis 1999; 18:23–9.
    1. United Nations Educational, Scientific, and Cultural Organization. Burkina Faso Country Profile. Available at: . Accessed 3 December 2018.
    1. Haidara FC, Tapia MD, Sow SO, et al. . Evaluation of a booster dose of pentavalent rotavirus vaccine coadministered with measles, yellow fever, and meningitis A vaccines in 9-month-old malian infants. J Infect Dis 2018; 218:606–13.
    1. Bharat Biotech International Ltd. Package insert - Typbar TCV. Andhra Pradesh, India: Bharat Biotech International Ltd.
    1. World Health Organization. Weekly epidemiological record. Geneva, Switzerland: World Health Organization, 2017.
    1. Sanofi Pasteur. IMOVAX Polio package insert. Available at: . Accessed 3 December 2018.
    1. Schmitt HJ, Zepp F, Müschenborn S, et al. . Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998; 157:208–14.
    1. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66:2093–8.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren